Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial

The Lancet

Volumn 383, Issue 9911, 2014, Pages 60-68

  Fitzgerald, Kevin ^a   Frank Kamenetsky, Maria ^a   Shulga Morskaya, Svetlana ^a   Liebow, Abigail ^a   Bettencourt, Brian R ^a   Sutherland, Jessica E ^a   Hutabarat, Renta M ^a   Clausen, Valerie A ^a   Karsten, Verena ^a   Cehelsky, Jeffrey ^a   Nochur, Saraswathy V ^a   Kotelianski, Victor ^a   Horton, Jay ^b   Mant, Timothy ^c   Chiesa, Joseph ^d   Ritter, James ^c   Munisamy, Malathy ^d   Vaishnaw, Akshay K ^a   Gollob, Jared A ^a   Simon, Amy ^a  

^a ALNYLAM PHARMACEUTICALS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c GUY S HOSPITAL   (United Kingdom)

^d 206 Carnegie Center   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALN PCS; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PLASMA PROTEIN; PROPROTEIN SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ALC PCS; ALC-PCS; PCSK9 PROTEIN, HUMAN;

ADULT; AGED; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; COMMON COLD SYMPTOM; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSURIA; ERYTHEMA; FEMALE; HEADACHE; HEMATOMA; HICCUP; HUMAN; LUNG EMBOLISM; MALE; MIDDLE AGED; NORMAL HUMAN; PARESTHESIA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POLYURIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; RNA INTERFERENCE; SINGLE BLIND PROCEDURE; YOUNG ADULT; BIOSYNTHESIS; BLOOD; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; GENE THERAPY; GENETICS; METHODOLOGY; MULTICENTER STUDY;

ADULT; CHOLESTEROL, LDL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC THERAPY; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERINE ENDOPEPTIDASES; SINGLE-BLIND METHOD;

EID: 84892741671     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61914-5     Document Type: Article

References (39)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004; 44: 720-32.
2. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Ther 2009; 31: 236-44.
3. Sniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD. Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol 2012; 6: 303-09.
4. Davidson MH, Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005; 96: 556-63.
5. Foley KA, Simpson RJ Jr, Crouse JR 3rd, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92: 79-81.
6. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
7. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-25.
8. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009; 25: 567-79.
9. Foody JM, Sajjan SG, Hu XH, et al. Loss of early gains in lowdensity lipoprotein cholesterol goal attainment among high-risk patients. J Clin Lipidol 2010; 4: 126-32.
10. Thomas JE, Tershakovec AM, Jones-Burton C, Sayeed RA, Foody JM. Lipid lowering for secondary prevention of cardiovascular disease in older adults. Drugs Aging 2010; 27: 959-72.
11. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34: 154-56.
12. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007; 32: 71-77.
13. Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem 2009; 284: 28856-64.
14. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
15. Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res 2009; 50 (suppl): S172-77.
16. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79: 514-23.
17. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 2007; 193: 445-48.
18. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA 2005; 102: 5374-79.
19. Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008; 49: 394-98.
20. Davignon J, Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009; 120: 163-73.
21. Costet P, Hoffmann MM, Cariou B, et al. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010; 212: 246-51.
22. Welder G, Zineh I, Pacanowski MA, Troutt JS, Cao G, Konrad RJ. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010; 51: 2714-21.
23. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18.
24. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012; 60: 1888-98.
25. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126: 2408-17.
26. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308: 2497-506.
27. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367: 1891-900.
28. Banerjee Y, Shah K, Al-Rasadi K. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 2425-26.
29. Milazzo L, Antinori S. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 2425.
30. Hooper AJ, Burnett JR. Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther 2013; 13: 429-35.
31. Meister G, Tuschl T. Mechanisms of gene silencing by doublestranded RNA. Nature 2004; 431: 343-49.
32. Vaishnaw AK, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics. Silence 2010; 1: 14.
33. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008; 105: 11915-20.
34. Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 2012; 51: 8529-33.
35. Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013; 3: 406-17.
36. Barros SA, Gollob JA. Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev 2012; 64: 1730-37.
37. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009; 94: 2537-43.
38. Adams SP, Tsang M, Wright JM. Lipid lowering efficacy of atorvastatin. Cochrane Database Syst Rev 2012; 12: CD008226.
39. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.